Preclinical Development Primer 201

Preclinical Development Primer 201 builds upon the established knowledge in Preclinical Development Primer 101, utilizing real-world examples and case studies to delve deep into the specific tests and data required to file a successful Investigational New Drug (IND) application. The class focuses first on efficacy, centered around pharmacology studies, including binding and potency assays, and second on safety, including ADME, hERG, DART, PK/PD, mutagenicity, and carcinogenicity testing. This primer examines each preclinical test’s goals and outcomes, evaluating data results to determine therapeutic margin, side effects, and optimal drug concentration. Finally, the class describes the workflow, timeline, and standards for validating and qualifying these tests. Don’t miss this opportunity to understand preclinical development―secure your spot today! 

Section 1: Overview

Discover key drug development metrics, including success rates, timelines, and costs. Get an overview of preclinical development, understand investigational new drug (IND) and clinical trial application (CTA) processes, and delve into pre-IND topics like pharmacology, pharmacokinetics, and toxicology.


Section 2: Pharmacology

Explore pharmacology essentials, including binding assays, dose-response curves, and drug mechanisms of action. Understand the design factors for drug products, and learn about challenges associated with animal models in this comprehensive course.

Section 3: Pharmacokinetics

Discover  the world of pharmacokinetics, covering ADME, regulatory compliance, bioanalytical assays, validation, and the measurement of pharmacokinetics and pharmacodynamics in this informative course. 

Section 4: Toxicology

Explore the intricacies of animal model and species selection in preclinical testing, understanding the concordance of animal and human toxicities, differences between species, and the significance of therapeutic margin and adverse effects.

Section 5: Nonclinical IND/CTA

Learn the essentials of the Common Technical Document (CTD) and its role in IND and CTA filings, including the various types of INDs and the FDA’s Animal Rule, with a focus on effective interpretation.

Five Takeaways


  1. State the FDA criteria necessary to support first-in-human clinical trials.
  2. List the required pharmacology assays, explain their purposes, and outline the criteria to move the candidate drug onto clinical trials.
  3. Analyze dose-response curves to estimate clinical starting dose levels.
  4. Name the required toxicology assays, list their purposes, and state the criteria to move the candidate drug onto clinical trials.
  5. Evaluate tissue culture and animal testing data to assess the drug candidate’s impact on safety.

Ready to get started?

Get in touch or enroll now

Powered By MemberPress WooCommerce Plus Integration